LACHUTE, QC, June 7, 2017 /CNW Telbec/ - H2 Biopharma Inc., a late---stage applicant Licensed Producer under the Access to Cannabis for Medical Purposes Regulations ("ACMPR") located in Lachute, Quebec, applauds the recently announced improvements to the licensing process managed by Health Canada.
Indeed, pursuant to these
H2 Biopharma is currently finalizing the construction of its 4500 square meters state---of---the---art, purpose---built production facility in Lachute, Quebec, on land totaling more than 180,000 square meter, leaving ample room for future expansions. The Company filed its license application late last year, and is currently undergoing the personal security screening stage. The process improvements announced by Health Canada may result in the Company receiving its production license ahead of schedule, allowing it to start growing quality---controlled cannabis under safe and secure conditions, for the benefit of Canadian patients.
Throughout the process, and despite significant internal expertise, the Company has been advised by industry veteran Georges Routhier, and its firm PipeDreemz, who have been providing advisory services to a number of successful Licensees, as well as security consultant Protect IP and its principal, Daniel Fontaine, who have played an integral part in ensuring that the company meets and exceeds all security requirements imposed by the Regulations. Andre Jerome, CEO of H2 Biopharma, stated: "Georges and Daniel have respectively seamlessly integrated in our team or internal and external professionals, and have provided top notch advices and services which have significantly contributed to our success to date. With the changed recently announced, we are looking forward to receiving our production license and both of them will definitely be able to claim some part of the credit when it happens."
About H2 Biopharma Inc. Established in 2014, H2 Biopharma Inc. was set up specifically for the production and distribution of medical marihuana, under the then MMPR regulations from Health Canada, since replaced by the ACMPR Framework. The Company has submitted its substantial License application in December 2016, and is finalizing the construction of its state---of---the---art production facility in Lachute, Quebec.
SOURCE H2 Biopharma Inc.
Subscribe to our Free Newsletters!
Angiogenesis is the process of formation of new blood vessels from pre-existing blood vessels. It ...
Aniridia is a genetic eye disorder in which the iris is partially or entirely absent. It is ...
Cachexia refers to severe muscle and fat loss, anorexia and marked weight loss due to an underlying ...View All